Boule Diagnostics AB (CHIX:BOULS) Short-Term Debt: kr129.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BOULS Boule Diagnostics AB CHIX:BOULS
47 GF Score
Price kr26.30
GF Value kr49.42
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Short-Term Debt?

Boule Diagnostics AB CHIX:BOULS 47 Short-Term Debt is kr129.2 Mil as of Mar. 2026. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review.

Boule Diagnostics AB's Short-Term Debt for the quarter that ended in Mar. 2026 was kr129.2 Mil.

Boule Diagnostics AB's quarterly Short-Term Debt increased from Sep. 2025 (kr123.9 Mil) to Dec. 2025 (kr129.8 Mil) but then declined from Dec. 2025 (kr129.8 Mil) to Mar. 2026 (kr129.2 Mil).

Boule Diagnostics AB's annual Short-Term Debt increased from Dec. 2023 (kr84.5 Mil) to Dec. 2024 (kr129.4 Mil) and increased from Dec. 2024 (kr129.4 Mil) to Dec. 2025 (kr129.8 Mil).

Boule Diagnostics AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Boule Diagnostics AB Short-Term Debt Related Terms

Boule Diagnostics AB Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Short-Term Debt Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.05 91.70 84.52 129.35 129.76

Boule Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.40 132.10 123.90 129.76 129.20
CHIX:BOULS
47GF Score
Boule Diagnostics AB CHIX:BOULS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of kr129.2 Mil mean?
Boule Diagnostics AB (CHIX:BOULS) has a Short-Term Debt of kr129.2 Mil as of Mar. 2026.
Is Boule Diagnostics AB's Short-Term Debt too high?
Boule Diagnostics AB's current Short-Term Debt is kr129.2 Mil. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Short-Term Debt compare to ABT and SYK?
Boule Diagnostics AB's Short-Term Debt of kr129.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Boule Diagnostics AB's current Short-Term Debt is kr129.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Short-Term Debt of kr129.2 Mil. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Short-Term Debt is kr129.2 Mil. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Short-Term Debt is kr129.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.

Key valuation signals for CHIX:BOULS:

  • Short-Term Debt: kr129.2 Mil
  • GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for CHIX:BOULS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.30
Price
kr49.42
GF Value